Carcinoid tumor with carcinoid heart disease: Tricuspid valve and pulmonary valve replacement in patients with Hedinger Syndrome and hepatic metastases

2012 ◽  
Vol 60 (S 01) ◽  
Author(s):  
F Hahnel ◽  
H Gulbins ◽  
S Blankenberg ◽  
H Reichenspurner
Author(s):  
Jef Van den Eynde ◽  
Connor P. Callahan ◽  
Mauro Lo Rito ◽  
Nabil Hussein ◽  
Horacio Carvajal ◽  
...  

Background Tricuspid regurgitation (TR) is a common finding in adults with congenital heart disease referred for pulmonary valve replacement (PVR). However, indications for combined valve surgery remain controversial. This study aimed to evaluate early results of concomitant tricuspid valve intervention (TVI) at the time of PVR. Methods and Results Observational studies comparing TVI+PVR and isolated PVR were identified by a systematic search of published research. Random‐effects meta‐analysis was performed, comparing outcomes between the 2 groups. Six studies involving 749 patients (TVI+PVR, 278 patients; PVR, 471 patients) met the eligibility criteria. In the pooled analysis, both TVI+PVR and PVR reduced TR grade, pulmonary regurgitation grade, right ventricular end‐diastolic volume, and right ventricular end‐systolic volumes. TVI+PVR, but not PVR, was associated with a decrease in tricuspid valve annulus size (mean difference, −6.43 mm, 95% CI, −10.59 to −2.27; P =0.010). Furthermore, TVI+PVR was associated with a larger reduction in TR grade compared with PVR (mean difference, −0.40; 95% CI, −0.75 to −0.05; P =0.031). No evidence could be established for an effect of either treatment on right ventricular ejection fraction or echocardiographic assessment of right ventricular dilatation and dysfunction. There was no evidence for a difference in hospital mortality or reoperation for TR. Conclusions While both strategies are effective in reducing TR and right ventricular volumes, routine TVI+PVR can reduce TR grade to a larger extent than isolated PVR. Further studies are needed to identify the subgroups of patients who might benefit most from combined valve surgery.


2016 ◽  
Vol 43 (4) ◽  
pp. 341-344 ◽  
Author(s):  
Pranav Loyalka ◽  
Michael Schechter ◽  
Angelo Nascimbene ◽  
Ajay Sundara Raman ◽  
Cezar A. Ilieascu ◽  
...  

Carcinoid heart disease presents as right-sided heart failure attributable to the dysfunction of the tricuspid and pulmonary valves. Although surgical valve replacement is the mainstay of treatment when patients become symptomatic, it is associated with substantial perioperative mortality rates. We present a case of severe pulmonary valve stenosis secondary to carcinoid heart disease, treated successfully with percutaneous valve replacement. A 67-year-old man with severe pulmonary valve stenosis was referred to our center for pulmonary valve replacement. The patient had a history of metastatic neuroendocrine tumor of the small bowel with carcinoid syndrome, carcinoid heart disease, and tricuspid valve regurgitation previously treated with surgical valve replacement. Because of the patient's severe chronic obstructive pulmonary disease and hostile chest anatomy seen on a computed tomographic scan dating from previous cardiothoracic surgery, we considered off-label percutaneous valve replacement a viable alternative to open-heart surgery. A 29-mm Edwards Sapien XT valve was successfully deployed over the native pulmonary valve. There were no adverse sequelae after the procedure, and the patient was discharged from the hospital the next day. This case report shows that percutaneous valve replacement can be a valid option in carcinoid heart disease patients who are not amenable to surgical valve replacement.


2016 ◽  
Vol 152 (5) ◽  
pp. 1333-1342.e3 ◽  
Author(s):  
Rio Nomoto ◽  
Lynn A. Sleeper ◽  
Michele J. Borisuk ◽  
Lisa Bergerson ◽  
Frank A. Pigula ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document